Monopar Therapeutics (MNPR) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Monopar Therapeutics (NASDAQ: MNPR) recently:

• 7/15/2026 – Monopar Therapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/13/2026 – Monopar Therapeutics was upgraded by Zacks Research from “hold” to “strong-buy”.
• 7/12/2026 – Monopar Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/30/2026 – Monopar Therapeutics had its price target raised by BTIG Research from $104.00 to $117.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Monopar Therapeutics was given a new $105.00 price target by UBS Group AG.
• 6/29/2026 – Monopar Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $105.00 price target on the stock.
• 6/27/2026 – Monopar Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/14/2026 – Monopar Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 6/6/2026 – Monopar Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/2/2026 – Monopar Therapeutics was given a new $105.00 price target by Piper Sandler.
• 6/2/2026 – Monopar Therapeutics had its “buy” rating reaffirmed by HC Wainwright.

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.